<< Read Full Article
<< Read Full Article
Senior writer Adam Feuerstein contributed to the reporting of this article.
Shares of Biogen Idec (BIIB Quote) and Elan(ELN Quote) sank deeper Friday on investor fears that additional cases of a serious brain infection in patients taking multiple sclerosis drug Tysabri may surface in the near future.
On a conference call early Friday to discuss the two confirmed cases of progressive multifocal leukoencephalopathy (PML) tied to Tysabri treatment, Biogen Idec officials refused to disclose or discuss the number of Tysabri patients overall suspected to be afflicted with the serious and potentially fatal brain infection. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet